Efficacy of acupuncture and moxibustion in adjuvant treatment of patients with novel coronavirus disease 2019 (COVID-19): A protocol for systematic review and meta analysis

Novel coronavirus has infected 4.33 million people in more than 200 countries in the current global outbreak of COVID-19. However, there is still no effective drug to treat the disease, and acupuncture and moxibustion is utilized as adjuvant therapy for the treatment of COVID-19 in China. Nine elect...

Full description

Saved in:
Bibliographic Details
Published inMedicine (Baltimore) Vol. 99; no. 28; p. e21039
Main Authors Zhang, Qiongshuai, Xu, Xiaohong, Sun, Shaoqian, Cao, Fang, Li, Jiannan, Qi, Xun, Ji, Guangcheng, Wang, Yufeng, Song, Bailin
Format Journal Article
LanguageEnglish
Published United States Wolters Kluwer Health 10.07.2020
Subjects
Acupuncture Therapy - methods
Betacoronavirus - isolation & purification
Combined Modality Therapy - methods
Coronavirus Infections - drug therapy
Coronavirus Infections - therapy
COVID-19
Humans
Meta-Analysis as Topic
Moxibustion - methods
Pandemics
Pneumonia, Viral - therapy
Research Design
SARS-CoV-2
Study Protocol Systematic Review
Systematic Reviews as Topic
Treatment Outcome
Online AccessGet full text

Cover

More Information
Summary:Novel coronavirus has infected 4.33 million people in more than 200 countries in the current global outbreak of COVID-19. However, there is still no effective drug to treat the disease, and acupuncture and moxibustion is utilized as adjuvant therapy for the treatment of COVID-19 in China. Nine electronic databases: PubMed, EMBASE, Cochrane library, Web of Science (WOS), Google Scholar, China National Knowledge Infrastructure (CNKI), Chinese Biomedical Literature Database (CBM), Chinese Scientific and Journal Database (VIP), Wan Fang database (Wanfang) and 2 clinical trials register platforms: Chinese Clinical Trial Registry (ChiCTR), ClinicalTrials.gov (www.ClinicalTrials.gov/) will be searched for RCTs of A&M for COVID-19. The screening process will be developed by 2 independent reviewers, and meta-analysis will be performed with RevMan (V5.3.5) software. The study results will be contributed to a scientific journal after peer-reviewed for publication. The study will provide up-to-date evidence of the effectiveness and safety of A&M for patients with COVID-19. CRD42020185776.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0025-7974
1536-5964
DOI:10.1097/MD.0000000000021039